Sort   by:  
 Page size 
UnknownEfficacy of a new technique - INtubate-RECruit-SURfactant-Extubate - "IN-REC-SUR-E" - in preterm neonates with respiratory distress syndrome: study protocol for a randomized controlled trial.

Background

Although beneficial in clinical practice, the INtubate-SURfactant-Extubate (IN-SUR-E) method is not successful in all preterm neonates with respiratory distress syndrome, with a reported failure rate ranging from 19 to 69 %. One of the possible mechanisms responsible for the unsuc...
S-EPMC4991115 | biostudies-literature
UnknownComparison of "IN-REC-SUR-E" and LISA in preterm neonates with respiratory distress syndrome: a randomized controlled trial (IN-REC-LISA trial).

Background

Surfactant is a well-established therapy for preterm neonates affected by respiratory distress syndrome (RDS). The goals of different methods of surfactant administration are to reduce the duration of mechanical ventilation and the severity of bronchopulmonary dysplasia (BPD); how...
S-EPMC11218154 | biostudies-literature
UnknownComparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.

Importance

Early treatment choice in relapsing-remitting multiple sclerosis (RRMS) is prognostically crucial, yet robust comparative data on cladribine vs sphingosine-1-phosphate receptor modulators (S1PRMs) in treatment-naive patients with RRMS are limited.

Objective

To compare the c...
S-EPMC12584038 | biostudies-literature
UnknownProspects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA.
We present possible observing scenarios for the Advanced LIGO, Advanced Virgo and KAGRA gravitational-wave detectors over the next decade, with the intention of providing information to the astronomy community to facilitate planning for multi-messenger astronomy with gravitational waves. We estimate...
S-EPMC5920066 | biostudies-literature
UnknownTocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.

Background

Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.

Methods

A multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study...
S-EPMC7576974 | biostudies-literature
Sort   by:  
 Page size